Enzymatic and Genetic Evaluation of Butyrylcholinesterase in Male Infertility

An enzyme involved in oxidative stress showed lower activity in infertile men — in a study of 55 total subjects

Journal: F&S Science | Published: 2026-01-07 | Type: Case-control study | PMID: 41513034 Authors: Habib R et al. (COMSATS University Islamabad; Grand Asian University Sialkot; Kent State University) Funding/COI: Funding not listed. All authors declare no conflicts of interest.

Summary

Butyrylcholinesterase (BChE) is a plasma enzyme with a poorly understood role in oxidative stress and sperm function. This Pakistani case-control study measured BChE enzymatic activity and genotyped two BCHE gene variants (rs3495, rs1803274) in fertile and infertile men. Both lower enzyme activity and specific genotypes were associated with infertility — but the entire dataset comprises 55 individuals, which makes every number in this paper nearly meaningless.

Claims

• Infertile men had significantly lower plasma BChE activity compared to fertile controls (specific values not reported in abstract)
• BCHE variant rs3495 associated with infertility risk in the dominant genetic model: OR = 21.67
• rs3495 allelic distribution association: OR = 3.30
• rs1803274 showed "robust association in all models" (no specific ORs given in abstract)
• Authors claim this is the first study linking BCHE variants to male infertility

Study Quality

This is a case-control study enrolling 55 subjects total — fertile and infertile combined. If split evenly, that's roughly 27 cases and 28 controls. At this sample size, genetic association studies are underpowered by construction; any odds ratio produced should be treated as a rough directional signal at best, noise at worst. An OR of 21.67 from ~27 cases does not mean BChE variants increase infertility risk 21-fold — it means the confidence intervals likely span from under 1 to over 500, and the estimate is essentially uninterpretable.

The methodology itself is standard — Ellman's spectrophotometric method for BChE activity, PCR-RFLP and ARMS-PCR for genotyping — no complaints there. But competent methods applied to an inadequate sample still produce unreliable results. No power calculation is mentioned in the abstract, no correction for multiple testing is noted, and no replication cohort exists.

Red Flags

• 55 subjects total — this is a pilot study masquerading as a finding
• OR of 21.67 is a statistical artifact, not a biological signal; with n≈27 per group, extreme point estimates are expected and uninformative without wide confidence intervals (not reported)
• No funding source listed — origin and independence of the work are unclear
• Conclusion leaps from a small association to "potential therapeutic target" in one sentence — that is not supported by this data
• No replication: authors themselves acknowledge this is the first such study, which means there is zero independent confirmation
• Abstract does not report confidence intervals, exact p-values, or allele frequencies — key numbers needed to evaluate the genetic findings

Strengths

• Dual approach (enzymatic activity + genotyping) addresses the same question from two angles, which is methodologically sensible
• Established, validated assay methods
• Clean COI disclosures
• Identifies a genuinely underexplored enzyme in male reproductive biology — the research question is legitimate

Verdict

The research question is fine. The execution is not. Fifty-five subjects cannot support a genetic association study, and an odds ratio of 21.67 generated from a sample this small is not a discovery — it is a consequence of small-n statistics. This paper's value is as a hypothesis-generating pilot, nothing more. If a well-powered study (minimum several hundred subjects, ideally multiple populations) replicated these findings, BChE would become genuinely interesting in male infertility research. Until then, treat the specific numbers here as placeholders, not evidence.